SteriPack, a contract design and manufacturing organization (CDMO) serving pharmaceutical and medical device industries, has officially changed its trading name to Ensera. The rebranding marks an expansion of services and a strategic shift in positioning to address evolving market needs.
According to company statements, Ensera encompasses services ranging from product design and development to device component manufacturing, assembly, packing, and supply chain management for global pharmaceutical and medical device clients. The organization also offers design consultancies through its unified entity, Ensera Design, which now incorporates the expertise of HS Design (US) and Kinneir Dufort (UK).
SteriPack, now Ensera, has provided cleanroom manufacturing for over three decades. The rebrand responds to increased industry demands driven by the growth of biologics and biosimilars, the rise of decentralized healthcare, and heightened focus on patient-centric device design. Ensera’s expanded capabilities are aimed at streamlining the transition from concept to commercial-scale production, particularly for complex drug-device combination products and devices with low-to-medium production volumes and high SKU mixes.
Ensera’s service portfolio includes:
- Product design and development
- Design for manufacture
- Component manufacture
- Manual and automated device assembly
- Component cleaning
- Sterile barrier packing and kitting
- Secondary pharmaceutical packing
- Labeling, serialization, and aggregation
- Sterilization management
- Regulatory, supply chain, and cold chain support
Ensera Design leverages integrated resources from its US and UK design consultants to support pharmaceutical, MedTech, consumer health companies, and start-ups. The focus includes user experience, human factors, product development, and compliance with healthcare regulations. Access to manufacturing resources enables rapid prototyping and scaling for commercial distribution.
With facilities in the United States, Europe, and Southeast Asia, Ensera indicates ongoing investments in infrastructure and capacity to support emerging healthcare innovations. The company emphasizes collaborative partnerships, aiming to help industry stakeholders address supply chain agility and complex device production.
Company leadership described the rebranding as a reflection of Ensera’s commitment to enabling better health outcomes through integrated design and manufacturing solutions. The transformation provides clients direct access to expanded expertise, infrastructure, and a comprehensive suite of services intended to accelerate innovation in the healthcare sector.